FTC Says FDA Biosimilar Naming Rules May Confuse Doctors
The U.S. Federal Trade Commission on Wednesday criticized the U.S. Food and Drug Administration's proposed rules requiring biosimilars to use unique names for their active ingredients, saying the rules might confuse...To view the full article, register now.
Already a subscriber? Click here to view full article